PRODUCT INFORMATION

Voruciclib

Item No. 29085

CAS Registry No.:	1000023-04-0
Formal Name:	2-[2-chloro-4-(trifluoromethyl) phenyl]-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methyl-3-pyrrolidinyl]-4H-1-benzopyran-4-one
MF:	$C_{22}H_{19}ClF_3NO_5$
FW:	469.8
Purity:	≥98%
UV/Vis.:	λ_{max}: 269 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Voruciclib is supplied as a crystalline solid. A stock solution may be made by dissolving the voruciclib in the solvent of choice, which should be purged with an inert gas. Voruciclib is soluble in the organic solvent DMSO.

Description

Voruciclib is a pan-inhibitor of cyclin-dependent kinases (CDKs; K_is = 0.626-9.1 nM).[1] It is selective for CDKs over male germ cell associated kinase (MAK) and intestinal cell kinase (ICK; K_is = 259 and 481 nM, respectively), in a panel of 48 kinases. Voruciclib decreases myeloid cell leukemia-1 (Mcl-1) levels and increases cleaved poly(ADP-ribose) polymerase (PARP) levels in six diffuse large B-cell lymphoma (DLBCL) cell lines when used at concentrations ranging from 0.5 to 5 µM. It reduces tumor growth by 56.3% in a Ri-1 mouse xenograft model when administered at a dose of 200 mg/kg.

Reference

1. Dey, J., Deckwerth, T.L., Kerwin, W.S., *et al.* Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk diffuse large B-cell lymphoma to BCL2 inhibition. *Sci. Rep.* **7(1),** 18007 (2017).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM